| Keywords: |
leukemia; histopathology; sorafenib; bevacizumab; treatment planning; pathophysiology; nuclear magnetic resonance imaging; positron emission tomography; magnetic resonance imaging; diagnostic accuracy; c reactive protein; prostate specific antigen; gastrointestinal stromal tumor; imatinib; computer assisted tomography; lung non small cell cancer; epidermal growth factor receptor 2; tomography, x-ray computed; editorial; antineoplastic activity; prostate cancer; medical education; curriculum; atherosclerosis; positron-emission tomography; radiopharmaceutical agent; scintiscanning; nuclear magnetic resonance spectroscopy; medical practice; nuclear medicine; kidney cancer; trastuzumab; screening test; single photon emission computer tomography; alzheimer disease; x ray; tomography, emission-computed, single-photon; apolipoprotein e
|
